Business Description
AbCellera Biologics Inc
NAICS : 541720
SIC : 3741
ISIN : CA00288U1066
Share Class Description:
HAM:8QQ: Ordinary SharesTotal Employee Number:
562Description
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.6 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -0.84 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 3.93 | |||||
Beneish M-Score | -0.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -45.3 | |||||
3-Year Book Growth Rate | -9.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -18.54 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.08 | |||||
9-Day RSI | 71.37 | |||||
14-Day RSI | 69.95 | |||||
3-1 Month Momentum % | 88.95 | |||||
6-1 Month Momentum % | 56.8 | |||||
12-1 Month Momentum % | 59.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.05 | |||||
Quick Ratio | 13.89 | |||||
Cash Ratio | 10.67 | |||||
Days Sales Outstanding | 206.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.6 | |||||
Shareholder Yield % | -3.1 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -249.84 | |||||
Net Margin % | -181.75 | |||||
EBITDA Margin % | -210.86 | |||||
FCF Margin % | -239.17 | |||||
OCF Margin % | -193.66 | |||||
ROE % | -14.69 | |||||
ROA % | -10.64 | |||||
ROIC % | -21.01 | |||||
3-Year ROIIC % | -146.2 | |||||
ROC (Joel Greenblatt) % | -45.58 | |||||
ROCE % | -15.36 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 29.15 | |||||
PB Ratio | 2.49 | |||||
Price-to-Tangible-Book | 2.73 | |||||
EV-to-EBIT | -10.03 | |||||
EV-to-Forward-EBIT | 12.03 | |||||
EV-to-EBITDA | -11.89 | |||||
EV-to-Forward-EBITDA | 10.67 | |||||
EV-to-Revenue | 25.06 | |||||
EV-to-Forward-Revenue | 6.74 | |||||
EV-to-FCF | -10.49 | |||||
Price-to-GF-Value | 1.41 | |||||
Price-to-Projected-FCF | 4.11 | |||||
| Price-to-Net-Current-Asset-Value | 7.98 | |||||
| Price-to-Net-Cash | 17.15 | |||||
Earnings Yield (Greenblatt) % | -9.97 | |||||
FCF Yield % | -8.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AbCellera Biologics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 67.938 | ||
| EPS (TTM) (€) | -0.413 | ||
| Beta | 1.8841 | ||
| 3-Year Sharpe Ratio | 0.37 | ||
| 3-Year Sortino Ratio | 0.67 | ||
| Volatility % | 79.45 | ||
| 14-Day RSI | 69.95 | ||
| 14-Day ATR (€) | 0.336169 | ||
| 20-Day SMA (€) | 5.5605 | ||
| 12-1 Month Momentum % | 59.83 | ||
| 52-Week Range (€) | 2.411 - 7.52 | ||
| Shares Outstanding (Mil) | 305.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AbCellera Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AbCellera Biologics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 120 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 17:00 | In 30 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 29 days | ||
| General meeting for 2026 | 2026-06-11 09:00 | 4.45 (+0.79%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 11:40 | 5.06 (-3.07%) | ||
| Bank of America Health Care Conference | 2026-05-13 17:00 | 3.91 (-8.87%) | ||
| First quarter earnings conference call for 2026 | 2026-05-11 17:00 | 4.29 (+3.25%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 4.29 (+3.25%) | ||
| KeyBanc Capital Markets Healthcare Forum | 2026-03-17 | 3.08 (+0.75%) |
Show
Entries
AbCellera Biologics Inc Frequently Asked Questions
What is AbCellera Biologics Inc(HAM:8QQ)'s stock price today?
The current price of HAM:8QQ is €6.86. The 52 week high of HAM:8QQ is €7.52 and 52 week low is €2.41.
When is next earnings date of AbCellera Biologics Inc(HAM:8QQ)?
The next earnings date of AbCellera Biologics Inc(HAM:8QQ) is 2026-08-07 Est..
Does AbCellera Biologics Inc(HAM:8QQ) pay dividends? If so, how much?
AbCellera Biologics Inc(HAM:8QQ) does not pay dividend.
Press Release
Articles on AbCellera Biologics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers